EGM
MAZE

Engineers Gate Manager’s Maze Therapeutics MAZE Stock Holding History

Engineers Gate Manager’s Portfolio MAZE Stock Details MAZE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$333K Sell
11,143
-3,967
-26% -$104K ﹤0.01% 1724
2026
Q1 		$451K Buy
+15,110
New +$667K 0.01% 1464
2025
Q3 		– Sell
-10,212
Closed -$125K – 2612
2025
Q2 		$125K Buy
+10,212
New +$106K ﹤0.01% 1970

Other funds holding MAZE

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return

Engineers Gate Manager's MAZE Position: Q2 2026 in Review

Engineers Gate Manager reduced its Maze Therapeutics (MAZE) stake by 26% in Q2 2026, selling an estimated $104K and leaving 11,143 shares worth $333K. The position accounts for ﹤0.01% of the portfolio, ranked #1724.

Engineers Gate Manager first reported a position in MAZE in Q2 2025 and has held it in 3 quarters since. The position peaked at $451K in Q1 2026. 162 funds tracked by Wall St. Rank hold MAZE as of Q2 2026.

  • Engineers Gate Manager held 11,143 shares of Maze Therapeutics worth $333K as of Q2 2026.
  • Engineers Gate Manager sold 3,967 Maze Therapeutics shares in Q2 2026, an estimated $104K.
  • Maze Therapeutics made up ﹤0.01% of Engineers Gate Manager's portfolio in Q2 2026, its #1724 holding.
  • Engineers Gate Manager first reported a position in Maze Therapeutics in Q2 2025 and has held it in 3 quarters since.
  • Engineers Gate Manager's Maze Therapeutics position peaked at $451K in Q1 2026.
  • 162 funds tracked by Wall St. Rank held Maze Therapeutics as of Q2 2026.

Based on Engineers Gate Manager's 13F filing for Q2 2026, filed 14 Aug 2026.